Pacira BioSciences, Inc. reported $180 million in sales, up 2.25% from the year earlier period for the June quarter. Unfortunately, the company’s operating profit plunged 70% on those sales.
| Pacira BioSciences, Inc. 2025 Report ($000s): Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $176,387 | $180,347 | 2.25% | $342,211 | $347,941 | 1.67% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $28,240 | $8,499 | -69.90% | $41,452 | $10,489 | -74.70% | |
| 16.01% | 4.71% | 12.11% | 3.01% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $0.39 | -$0.11 | -128.21% | $0.58 | $0.00 | -100.00% | |
| 2026 Sales Estimate | 2025 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $785,000 | 4.33% | $751,660 | 6.65% | |||
Source: RRY Publications LLC
Pacira’s Q2: Growth on Paper, Pain in the Margins
Pacira BioSciences walked into its Q2 2025 earnings call with a classic orthopedic business paradox: sales creeping upward, profits collapsing downward.
Revenue came in at $180 million, a modest 2.25% year-over-year gain. But operating profit? It fell off a cliff—down 70%.
That didn’t stop CEO Frank Lee from dressing the wound with upbeat language, assuring analysts that the company delivered “solid execution” and is on track with its “5×30 path to growth and value creation.”
Translation: Pacira is leaning on two pillars — commercial growth (mainly EXPAREL) and pipeline bets (such as PCRX-201).
The Good News
- EXPAREL: Despite a softening surgical volume environment, Pacira reported encouraging traction in outpatient settings — particularly hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). A new Centers for Medicare and Medicaid Services (CMS) policy starting in 2026, which phases out the inpatient-only list and shifts hundreds of procedures into ASC coverage, could expand EXPAREL’s playing field dramatically.
- Debt reduction: The balance sheet looks healthier, always a welcome sign for investors.
- ZILRETTA partnership: Teaming up with Johnson & Johnson MedTech gives ZILRETTA broader reach. Doubling the sales force overnight, courtesy of J&J, is no small advantage in the osteoarthritis (OA) pain space.
The Not-So-Good News
- Margins are under pressure. Growing sales while profits evaporate is never a sustainable story for Wall Street.
- Surgical volumes are flat-to-down. Outpatient volumes dipped slightly versus last year; inpatient stayed flat. Pacira’s growth in ASCs is encouraging — but it’s happening against a sluggish backdrop.
- Pipeline risk. EXPAREL remains the anchor, but true upside depends on delivering pipeline assets like PCRX-201. Until then, Pacira lives and dies by its flagship franchise.
Analyst Pressure
Needham’s John Gionco pressed leadership on surgical volume dynamics and growth strategy. CCO Brendan Teehan’s response emphasized:
- Targeting regional payer plans for alignment with surgical opportunities.
- Building reimbursement wins outside the bundle through NOPAIN initiatives.
- Staying “opportunistic” in capturing volume where possible.
Encouraging? Yes. Sufficient to offset collapsing margins? That’s less clear.
Executive Take-Home
For analysts and investors watching Pacira, the quarter underscores three key themes:
- Outpatient is the battleground. CMS’s 2026 move to phase out the inpatient-only list could supercharge EXPAREL adoption in ASCs and HOPDs. Every orthopedic company should be modeling for this shift.
- Partnerships matter. The J&J MedTech collaboration instantly scales ZILRETTA’s reach — an instructive play for mid-cap companies trying to punch above their salesforce weight.
- Margins tell the truth. Sales growth is nice, but operating profit tells the real health story. Pacira has yet to show how its strategic moves translate into bottom-line recovery.
Pacira’s Q2 was less about results and more about promises. For investors, the lesson is clear: the shift to outpatient orthopedics is real, partnerships can turbocharge distribution, but profit discipline remains the toughest operation of all.
